Loading…
Damora Therapeutics, Inc. is projected to rise to $32.23 by 2027, a +10% move from its current price of $29.21. DMRA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $27.99 | $29.20 | $30.47 | -0.02% |
| Aug 2 | $27.49 | $29.20 | $31.01 | -0.04% |
| Aug 3 | $27.12 | $29.19 | $31.43 | -0.05% |
| Aug 4 | $26.81 | $29.19 | $31.78 | -0.07% |
| Aug 5 | $26.53 | $29.18 | $32.10 | -0.09% |
| Aug 6 | $26.29 | $29.18 | $32.39 | -0.11% |
| Aug 7 | $26.07 | $29.17 | $32.65 | -0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $26.07 | $29.17 | $32.65 | -0.13% |
| Week 2 | $24.85 | $29.14 | $34.17 | -0.25% |
| Week 3 | $23.94 | $29.10 | $35.37 | -0.38% |
| Week 4 | $23.20 | $29.06 | $36.41 | -0.50% |
| Week 5 | $22.56 | $29.03 | $37.34 | -0.63% |
| Week 6 | $22.00 | $28.99 | $38.20 | -0.76% |
| Week 7 | $21.49 | $28.95 | $39.01 | -0.88% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. Its lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia.
Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Damora Therapeutics, Inc. (DMRA) is a healthcare stock with current price $28.33 and market capitalization $1.74B. It occupies a position in the sector with a sizable market footprint, reflecting a substantive presence in its niche of hematologic disorder therapies.
The price outlook presented through the year-by-year forecast shows a path of growth across the horizon, with higher average prices projected in later years than the current level.
A major floor 45.1% below — a decisive break under it would weaken the trend.
The nearest floor, 27.3% below — buyers have tended to step in here.
The nearest ceiling, 12.9% above — a clean break opens room to run.
A major ceiling 35.5% above — clearing it would confirm fresh momentum.
Key DMRA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DMRA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $29.04 | Buy | $29.22 | Sell |
| MA 10 | $30.18 | Sell | $29.50 | Sell |
| MA 20 | $29.93 | Sell | $28.96 | Buy |
| MA 50 | $25.86 | Buy | $27.13 | Buy |
| MA 100 | $25.41 | Buy | $25.66 | Buy |
| MA 200 | $23.68 | Buy | $22.47 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.89 | Neutral |
| Stoch RSI (14) | 17.63 | Buy |
| CCI (20) | -43.48 | Neutral |
| Williams %R (14) | -75.75 | Info |
| MACD (12,26,9) | -0.44 | Sell |
| ROC (12) | -5.74 | Sell |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 24.25 | Neutral |
| TRIX (15) | 0.85 | Buy |
| Awesome (5,34) | 2.04 | Buy |
| Ultimate (7,14,28) | 36.32 | Neutral |
| Momentum (10) | -1.03 | Sell |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 28.50 | Buy |
| ADX (14) | 16.68 | Neutral |
| ATR (14) | 1.07 | Info |
The 30-day technical picture is bullish. RSI14 sits at 50, with the 50-day simple moving average at $25.77 and the 200-day simple moving average at $23.60, suggesting a constructive trend. Near-term resistance is identified at $32.99 and support at $20.59, framing a potential upside if momentum strengthens.
Over the last 30 days, the price traded within a range roughly between $21.29 and $37.70, indicating notable volatility within a defined band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $18.14 | $29.21 | $38.56 | 0% | Neutral | |
| $24.39 | $32.23 | $45.72 | +10% | Neutral | |
| $25.29 | $35.01 | $52.44 | +20% | Neutral | |
| $24.11 | $34.72 | $54.21 | +19% | Neutral | |
| $26.78 | $39.95 | $64.57 | +37% | Bullish | |
| $38.00 | $58.55 | $97.49 | +100% | Bullish | |
| $39.58 | $62.88 | $107.52 | +115% | Bullish | |
| $39.34 | $64.34 | $112.67 | +120% | Bullish | |
| $41.17 | $69.25 | $123.93 | +137% | Bullish | |
| $37.67 | $65.10 | $118.87 | +123% | Bullish | |
| $59.15 | $116.09 | $230.33 | +297% | Bullish | |
| $119.64 | $265.88 | $593.50 | +810% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $18.14 | $29.21 | $34.16 | +0.00% |
| August 2026 | $23.97 | $28.47 | $34.85 | -2.53% |
| September 2026 | $23.88 | $28.73 | $35.89 | +0.92% |
| October 2026 | $24.72 | $30.07 | $38.17 | +4.65% |
| November 2026 | $24.47 | $30.03 | $38.61 | -0.14% |
| December 2026 | $23.97 | $29.65 | $38.56 | -1.28% |
Click any year to see its month-by-month DMRA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, DMRA could reach as high as $38.56, with a base case around $29.21 and support toward $18.14 — roughly 0% from $29.21. A consolidation phase looks the most probable path here.
Expect DMRA to range from $24.39 to $45.72 through 2027. The $32.23 average target implies a +10% move from current prices. That is up +10% on the projected 2026 average. Price action looks broadly range-bound.
The DMRA price prediction for 2028 points to an average of $35.01 (low $25.29, high $52.44) — a potential gain of +20% on today's $29.21. A consolidation phase looks the most probable path here.
In 2029, DMRA is projected to trade between $24.11 and $54.21, averaging $34.72 — a potential gain of +19% from today's $29.21. That is -1% versus the projected 2028 average. Price action looks broadly range-bound.
Damora Therapeutics, Inc.'s 2030 outlook centres on $39.95, within a $26.78 to $64.57 range. That is up +15% on the projected 2029 average. That marks a +37% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, DMRA could reach as high as $97.49, with a base case around $58.55 and support toward $38.00 — roughly +100% from $29.21. Momentum favours further upside here.
Expect DMRA to range from $39.58 to $107.52 through 2032. The $62.88 average target implies a +115% move from current prices. That is up +7% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The DMRA price prediction for 2033 points to an average of $64.34 (low $39.34, high $112.67) — a potential gain of +120% on today's $29.21. Momentum favours further upside here.
In 2034, DMRA is projected to trade between $41.17 and $123.93, averaging $69.25 — a potential gain of +137% from today's $29.21. That is up +8% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Damora Therapeutics, Inc.'s 2035 outlook centres on $65.10, within a $37.67 to $118.87 range. That is -6% versus the projected 2034 average. That marks a +123% change versus current levels. Momentum favours further upside here.
By 2040, DMRA could reach as high as $230.33, with a base case around $116.09 and support toward $59.15 — roughly +297% from $29.21. Buyers look set to stay in control over this stretch.
Expect DMRA to range from $119.64 to $593.50 through 2050. The $265.88 average target implies a +810% move from current prices. That is up +129% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in DMRA today (≈ 34.234851 DMRA) could be worth
$9,102.19
+$8,102.19 (+810%) by 2050 · US Dollar
Based on the average projected DMRA price of $265.88 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DMRAwould be worth at today's price.
$1,000 invested in DMRA on Jul 30, 2025 (≈ 301.204825 DMRA) would be worth
$8,798.19
+$7,798.19 (+779.8%) today · 8.80× · US Dollar
Based on a DMRA entry price of $3.32 vs. today's $29.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $29.17 | $1,001.37 | +0.1% |
| 1 month ago | $26.01 | $1,123.03 | +12.3% |
| 3 months ago | $25.36 | $1,151.81 | +15.2% |
| 6 months ago | $26.24 | $1,113.4 | +11.3% |
| 1 year ago | $3.32 | $8,798.19 | +779.8% |
| All time (5.0y) ago | $109.75 | $266.15 | -73.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DMRA forecast.
Our base-case forecast reaches $58.00 around 2031.
Implied market cap at $58.00: $3.57B
The multi-year forecast shows a progression in average values from 2026 onward. In 2026, the avg is $28.33 with a min of $18.14 and a max of $37.33 and ROI of 0, signaling a neutral near-term stance. By 2030, the avg rises to $36.22 with ROI of 27.8 and a bullish tilt to the longer horizon.
The years 2031–2035 continue the bullish trajectory, with 2031 avg $52.75, 2032 $56.68, 2033 $57.66, 2034 $61.50 and 2035 $57.27, all carrying positive ROIs (86.2, 100.1, 103.5, 117.1, and 102.2 respectively). The forecast then accelerates markedly toward 2040, where the avg is $100.06 and ROI is 253.2, followed by 2050 with an avg of $224.39 and ROI of 692, both signaling strong upside potential. The sentiment shifts to bullish in the later years (2030 onward) as these higher-average outcomes emerge, though these figures remain estimates and are not guarantees.
Tap a question to reveal the answer.
The 2026 forecast shows an avg of $28.33, with a min of $18.14 and a max of $37.33; ROI is 0 and sentiment is Neutral.
Forecasts indicate positive upside beyond 2026, with 2030 avg $36.22 and ROI 27.8, and 2050 avg $224.39 with ROI 692. These are estimates, not guarantees, and should not be considered financial advice.
Yes, the 2040 forecast shows an avg of $100.06 with a min of $50.31 and a max of $200.04; ROI is 253.2 and sentiment is Bullish.
The 2030 forecast lists an avg of $36.22, ROI 27.8, and a Bullish sentiment, with a min of $24.14 and a max of $58.84.
The 2050 forecast shows an avg of $224.39, a min of $100.97, a max of $505.34, ROI 692, and a Bullish sentiment.
Damora Therapeutics, Inc. Community Discussion
0Share your Damora Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.